retatrutide weight loss trial data results in 28 percent average 28.7% Weight Loss in New
Description
pmid:22290181 72
Daily transdermal gels maintain more stable levels and appear to carry lower acne risk (Abou Chawareb et al., 2026)
Research in earlier phases or small trials include evaluation of GLP-1s for cystic fibrosis-related diabetes, polycystic ovarian syndrome (PCOS), chronic obstructive pulmonary disease (COPD), Prader-Willi syndrome (PWS), asthma, substance or alcohol use disorder and as add-on to insulin for type 1 diabetes
The LIGHT trial was terminated early, limiting long-term conclusions, but no oncogenic signals were observed during follow-up [15]
Some studies found that people who took GLP-1 medications reported higher levels of anxiety than control groups
